Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

MERCK AND CO : Merck, Wyeth shares stumble on drug concerns

10/22/2008 | 11:17am EDT

NEW YORK (Reuters) - Merck & Co said on Wednesday it will slash 12 percent of its workforce and tempered its long-range earnings outlook, and Wyeth announced a delay in its closely watched experimental Alzheimer's disease drug, highlighting some of the troubles facing the industry.

By Bill Berkrot

Difficult economic conditions and a reversal in favorable foreign currency exchange rates will further compound the impact of patent expirations of lucrative medicines, few major new drugs on the immediate horizon and a tougher regulatory climate in an industry that has already been going through serious belt tightening.

"If we don't change the business models we're not going to survive as an industry," Merck <MRK.N> CEO Richard Clark said on a conference call with analysts and investors.

"Our current sales trends for key products, compounded by known industry and emerging economic factors, have led us to reassess the environment in which we expect to be operating between now and 2010," Clark said in a statement.

Wyeth <WYE.N> reported flat third-quarter profit in line with Wall Street expectations as it was hit by generic competition for its Protonix acid reflux drug.

Wyeth raised only the low end of its full-year forecast by 2 cents, but its failure to raise the forecast overall and the setback for its babineuzumab Alzheimer's drug spooked investors and its shares fell 8 percent.

GlaxoSmithKline Plc <GSK.L>, the world's second-largest drugmaker, provided a glimmer of stability, reporting that its profit before restructuring charges rose 6 percent, topping analysts' forecasts, as sales rose 7 percent for the quarter.

But the British company stuck to its cautious full-year forecast for a mid-single-digit decline in earnings per share in local currencies.

Merck's third-quarter net profit fell 28 percent, and its shares were off 1 percent.

It said 6,800 employees will lose their jobs and another 400 vacancies will not be filled. Those cuts come on top of 10,400 jobs that were slashed in an earlier restructuring.

Wyeth said it still expects to reduce its head count 4 percent to 6 percent this year and by 10 percent over several years.

"As the top line has been slowing and in some cases declining, pharmaceutical firms are reacting aggressively with job cuts," Morningstar analyst Damien Conover said.

Both Merck and Wyeth said results were hurt by exposure to financial institutions that succumbed to the global credit crisis. And both were helped by favorable foreign currency exchange rates, a trend that has begun to reverse.

Merck said its global restructuring should result in cumulative savings of $3.8 billion to $4.2 billion from 2008 to 2013.

"It's clear that companies across the board are working hard to reduce expenses," said Caris & Co analyst David Moskowitz.

(Additional reporting by Ransdell Pierson and Lewis Krauskopf; Editing by Maureen Bavdek)

ę Reuters 2008
All news about MERCK & CO., INC.
07/23MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combinat..
07/22ADAGENE : Agrees With Merck on Trials of Its Monoclonal Antibodies With Keytruda..
07/22MERCK : Eisai Win US FDA Approval of Keytruda Plus Lenvima Combination for Certa..
07/22MERCK : FDA Approves KEYTRUDA« (pembrolizumab) Plus LENVIMA« (lenvatinib) Combin..
07/22FDA Approves KEYTRUDA« (pembrolizumab) Plus LENVIMA« Combination for Patients..
07/21MERCK : Teams up with Noxxon to Evaluate NOX-A12 in Combination With Keytruda in..
07/21NOXXON Pharma N.V. Enters Second Clinical Collaboration with Merck & Co., Inc..
07/21BAYER : Heart Failure Treatment Wins EU Market Authorization
07/21MERCK : Secures European Approval for Verquvo for Chronic Heart Failure
07/21MERCK : VERQUVO« (vericiguat) Approved in the European Union
More news
Financials (USD)
Sales 2021 46 551 M - -
Net income 2021 12 867 M - -
Net Debt 2021 11 752 M - -
P/E ratio 2021 16,5x
Yield 2021 3,37%
Capitalization 196 B 196 B -
EV / Sales 2021 4,47x
EV / Sales 2022 4,06x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 77,54 $
Average target price 94,10 $
Spread / Average Target 21,4%
EPS Revisions
Managers and Directors
Kenneth C. Frazier Chairman & Chief Executive Officer
Robert M. Davis President
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-5.21%195 475
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
NOVARTIS AG1.10%207 246